Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx)-Reference-Cited by-同舟云学术

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx)

Published:2017-04 Issue:2 Volume:72 Page:257-267
ISSN:0040-5957
Container-title:Therapies
language:en
Short-container-title:Therapies

Author:

Lamoureux Fabien,Duflot Thomas

Publisher

Elsevier BV

Subject

Pharmacology (medical)

Reference28 articles.

1. The largest prospective warfarin-treated cohort supports genetic forecasting;Wadelius;Blood,2009

2. Estimation of the warfarin dose with clinical and pharmacogenetic data;International Warfarin Pharmacogenetics Consortium;N Engl J Med,2009

3. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose;Rieder;N Engl J Med,2005

4. Genetic determinants of response to warfarin during initial anticoagulation;Schwarz;N Engl J Med,2008

5. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2;Rost;Nature,2004

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empowering personalized pharmacogenomics with generative AI solutions;Journal of the American Medical Informatics Association;2024-03-06

2. Genetic Determinants of Response to Statins in Cardiovascular Diseases;Current Cardiology Reviews;2024-03

3. Empowering Personalized Pharmacogenomics with Generative AI Solutions;2024-02-27

4. Cardiovascular pharmacogenomics – Molecular basis of protective and adverse drug response;Genomic and Molecular Cardiovascular Medicine;2024

5. PAnno: A pharmacogenomics annotation tool for clinical genomic testing;Frontiers in Pharmacology;2023-01-26